The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NMRA | -87.75% | N/A | N/A | -89% |
| S&P | +14.5% | +93.32% | +14.09% | +51% |
Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.02M | 88.1% |
| Market Cap | $118.61M | -92.4% |
| Market Cap / Employee | $1.24M | 0.0% |
| Employees | 96 | 0.0% |
| Net Income | -$52.73M | 10.2% |
| EBITDA | -$54.02M | 15.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $124.52M | -17.4% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $19.79M | 0.0% |
| Short Term Debt | $0.17M | -95.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -80.25% | -8.5% |
| Return On Invested Capital | -56.52% | -9.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$52.40M | 6.7% |
| Operating Free Cash Flow | -$52.40M | 6.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 5.54 | 5.30 | 0.56 | 0.52 | -85.92% |
| Price to Tangible Book Value | 5.54 | 5.30 | 0.56 | 0.52 | -85.92% |
| Enterprise Value to EBITDA | -23.12 | -22.30 | 1.25 | 1.46 | -107.80% |
| Return on Equity | -70.5% | -64.5% | -79.0% | -89.4% | 15.95% |
| Total Debt | $2.75M | $1.85M | $0.94M | $19.96M | 453.40% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
